ERBB2 and neoplasm: To assess the advantage of the HER2-expressing tumor-targeting selectivity property of HCT-mono-mIL12, we treated BALB/c mice bearing the dual-flank tumors with HCT-mono-mIL12, once reaching an average tumor volume of approximately 300 mm3, via i.p. injection at 1.6 μg per dose (approximately 80 μg/kg per dose; an equimolar amount of 0.5 μg rmIL12 per dose) twice a week for a total of six doses (Figure 2C).